Skip to main
EXEL
EXEL logo

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 22%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. demonstrates a positive trajectory in its financial outlook, particularly bolstered by the continued success of cabozantinib (Cabo) in treating various cancers, including renal cell carcinoma (RCC) and neuroendocrine tumors (NETs), supported by recent label expansions and favorable data from clinical trials. The promising performance of zanzalintinib, especially in the treatment of metastatic colorectal cancer (mCRC), provides a strong indication of growth potential beyond Cabo, reflecting confidence in Exelixis's future product pipeline. Overall, the firm’s ability to deliver statistically significant improvements in survival rates and its strong positioning in key markets suggest a robust foundation for sustained revenue growth and competitive advantage.

Bears say

Exelixis Inc. faces a significant financial challenge due to the anticipated patent cliff in 2031, which is projected to result in an 80% revenue decline by 2032, surpassing the Street's expectation of a 68% drop. The company is also exposed to various competitive risks, including potential market share erosion for its key drug cabozantinib in renal cell carcinoma and disappointing performance in new indications. Additionally, uncertainties surrounding approval timelines and the potential for generic entry could further jeopardize Exelixis's revenue stability and overall financial outlook.

Exelixis (EXEL) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 22% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 18 analysts, Exelixis (EXEL) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.